Clinical trial NCT05903456: Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma
Official title: Icaritin Soft Capsule Combined With Lenvatinib and Transcatheter Arterial Chemoembolization（TACE） for the Treatment of Hepatocellular Carcinomaunresectable, Non-metastatic Hepatocellular Carcinoma
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Hepatocellular Carcinoma
Keywords: Hepatocellular carcinoma; Icaritin soft capsules;TACE; lenvatinib
Lead sponsor: Zhejiang Cancer Hospital
Sponsor class: OTHER
First posted: 2023-06-15
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The investigators design a phase II clinical study to explore the efficacy and safety of Transarterial Chemoembolization (TACE) + Lenvatinib + Icaritin soft capsules in patients with Unresectable, non-metastatic hepatocellular carcinoma and to analyze potential biomarkers of therapeutic response.

Detailed description: This is a single-center, open-label, prospective, non-randomized clinical trial. We adopted the prospective cohort study to explore the safety and efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Icaritin soft capsules in the patients with Unresectable, non-metastatic hepatocellular carcinoma.

It is estimated that 20 patients who met the study criteria will be enrolled in Zhejiang Cancer Hospital. The investigators will follow up and collect subjects' data monthly to evaluate the efficacy and safety of treatment, including overall survival and time to progression. Multi-omics data analysis will be used to find potential biomarkers of treatment response.

Eligibility criteria: Inclusion Criteria:

1. Between the ages of 18 and 80;
2. Patients with histological/cytological confirmed hepatocellular carcinoma.
3. HCC patients eligible for China liver cancer staging (CNLC) Stage IIIa, which cannot be resectable, are not suitable for radical treatment.
4. According to the RECIST v1.1 standard, there must be at least one measurable lesion on the upper abdominal enhanced CT or MRI.
5. Child-Pugh grade A or B;
6. ECOG physical condition score is 0 or 1;
7. Suitable for the indications of TACE surgery and chemotherapy drugs prescribed in advance by the research center, without any contraindications.
8. Regular antiviral therapy should be given if HBV or HCV infection is present.
9. Life expectancy is more than 3 months
10. Able to swallow and absorb oral tablets;
11. Appropriate organ function with the following laboratory test values obtained within 7 days prior to therapeutic use:
12. (hemoglobin value ≥80g/L, neutrophil count ≥2.5×109/L, platelet count ≥75×109/L, serum total bilirubin ≤2× upper limit of normal (UNL), aspartic transferase ≤2×UNL, alanine transferase ≤3×UNL, serum creatinine ≤1.5×UNL)
13. Manageable blood pressure
14. Women of childbearing age must already be using reliable contraception or have had a negative pregnancy test (serum or urine) within 7 days prior to enrollment and be willing to use an effective method of contraception during the trial period and within 2 months after the last drug administration. Male subjects whose partners are women of childbearing age should use effective methods of contraception during the trial period and within 2 months after the last dose;
15. The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with follow-up.

Exclusion Criteria:

1. Formation of portal vein main cancer thrombus or extensive cancer thrombus.
2. HCC was treated with local treatment of existing lesions (e.g., TACE, ablation, particle, TARE, hepatic arterial infusion chemotherapy, or radiotherapy).
3. Patients who have previously received targeted or immunoreactive anti-tumor therapy for HCC and chemotherapy need to be desensitized for more than one month.
4. Subjects were unable to perform enhanced CT or MRI scans of the liver.
5. Have a history of liver transplantation or are currently candidates for liver transplantation.
6. Patients at high risk for esophageal or gastric variceal bleeding or unproven severe variceal bleeding within the last 3 months.
7. Have bleeding or thrombotic disease or are receiving thrombolytic therapy
8. Study clinically significant hemoptysis or tumor hemorrhage of any cause within 2 weeks prior to initial administration of the intervention.
9. Study of significant cardiovascular impairment in the 12 months prior to initial administration, such as a history of congestive heart failure above NYHA Grade II (Appendix 12), unstable angina, myocardial infarction or cerebrovascular stroke, or arrhythmias associated with hemodynamic instability.
10. There was clinically significant ascites on physical examination, which could not be controlled by drugs.
11. Known to be allergic to any component of icartin soft capsules and lenvatinib preparation.
12. Pregnant or lactating female patients.
13. Other conditions in which participation in the study is not appropriate according to the investigator's judgment.

Primary outcomes:
measure: Objective Response Rate
timeFrame: 48 weeks
Secondary outcomes:
measure: progression-free survival
timeFrame: 96 weeks
measure: Overall Survival
timeFrame: 96 weeks
measure: Disease Control Rate
timeFrame: 48 weeks
measure: Duration of Response
timeFrame: up to 48 weeks
measure: adverse event
timeFrame: 96 weekes
Other outcomes:
Locations:
Study officials:
References: